Mark Gustavson is a dedicated biotechnology professional with over 20 years of experience in translational and clinical oncology research and development, specializing in digital and computational pathology. They have held various leadership roles, including positions at AstraZeneca and MetaStat, Inc., where they developed advanced diagnostic tests and led teams in the creation of state-of-the-art CLIA laboratories. Mark has also contributed to regulatory processes at the FDA and has extensive knowledge in biomarker development and assay validation. They earned a PhD in Oncology and Cancer Biology from Vanderbilt University School of Medicine.
This person is not in any teams
This person is not in any offices